Saleh, Mohamed

Saleh, Mohamed was paid $364K by Medicaid between Mar 2019 and Nov 2024, across 16 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 53% of everything it billed.

Compared with peers

Next to other Chiropractor providers in Michigan

Rank by total paid#26 of 853

Median peer was paid$38K

This provider vs. median9.5×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	166	$8K
2020	208	$44K
2021	15	$204.73
2022	1,064	$128K
2023	946	$103K
2024incomplete	1,196	$80K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	53%	887	699	$192K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	23%	1,084	865	$85K
J2315	Injection, naltrexone, depot form, 1 mg	9.8%	29	28	$36K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	6.0%	194	167	$22K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	3.9%	900	689	$14K
99203	Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity	1.2%	77	69	$4K
99222	Initial hospital care, per day, moderate complexity	<1%	68	65	$4K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	20	20	$3K
80305		<1%	174	139	$2K
99238	Hospital discharge day management, 30 minutes or less	<1%	41	39	$1K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	26	24	$781.42
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	14	14	$210.84

4 more codes

99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	15	$204.73
96110	Developmental screening, with scoring and documentation, per standardized instrument	<1%	13	$141.44
36415	Collection of venous blood by venipuncture	<1%	13	$101.85
97802		0%	40	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.